Evidence map›Paper›PMID 37976012›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2024

Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis.

Carolyn A Young, David J Rog, Basil Sharrack, Radu Tanasescu, Seema Kalra, Timothy Harrower, Alan Tennant, Roger J Mills, Trajectories of Outcome in Neurological Conditions-MS Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Multiple sclerosis relapse risk factors across treatment eras.Multiple sclerosis journal - experimental, translational and clinical
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carolyn A YoungWalton Centre NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK, University of Liverpool, Liverpool, UK. Cayoung@liverpool.ac.uk.ORCID http://orcid.org/0000-0003-1745-7720
David J RogManchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust, Salford, UK.
Basil SharrackAcademic Department of Neurology, University of Sheffield, Sheffield, UK.
Radu TanasescuUniversity of Nottingham, Nottingham, UK.
Seema KalraUniversity Hospital of North Midlands NHS Trust, Stoke-On-Trent, UK.
Timothy HarrowerUniversity of Exeter Medical School, Exeter, UK.
Alan TennantLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Roger J MillsWalton Centre NHS Foundation Trust, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK, University of Liverpool, Liverpool, UK.
Trajectories of Outcome in Neurological Conditions-MS Study Group

Funding

Multiple Sclerosis Society C009-16.1
6 · The paper itself

Abstract

BACKGROUND AND

aimsIn people with relapsing-remitting multiple sclerosis (pwRRMS), data from studies on non-pharmacological factors which may influence relapse risk, other than age, are inconsistent. There is a reduced risk of relapses with increasing age, but little is known about other trajectories in real-world MS care.

methodsWe studied longitudinal questionnaire data from 3885 pwRRMS, covering smoking, comorbidities, disease-modifying therapy (DMT), and patient-reported outcome measures, as well as relapses during the past year. We undertook Rasch analysis, group-based trajectory modelling, and multilevel negative binomial regression.

resultsThe regression cohort of 6285 data sets from pwRRMS over time showed that being a current smoker was associated with 43.9% greater relapse risk; having 3 or more comorbidities increased risk and increasing age reduced risk. Those diagnosed within the last 2 years showed two distinct trajectories, both reducing in relapse frequency but 25.8% started with a higher rate and took 4 years to reduce to the rate of the second group. In the cohort with at least three data points completed, there were three groups: 73.7% followed a low stable relapse rate, 21.6% started from a higher rate and decreased, and 4.7% had an increasing then decreasing pattern. These different trajectory groups showed significant differences in fatigue, neuropathic pain, disability, health status, quality of life, self-efficacy, and DMT use.

conclusionsThese results provide additional evidence for supporting pwRRMS to stop smoking and underline the importance of timely DMT decisions and treatment initiation soon after diagnosis with RRMS.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingHealth StatusHumansQuality of LifeRecurrenceMultiple sclerosisPatient-reported outcome measureRaschRelapseTrajectories of Outcome in Neurological Conditions-MS

Identifiers

PMID37976012
PMCPMC11021238

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.